Owlstone Medical Stock

Owlstone Medical is developing a breathalyzer for the early detection of cancer and other inflammatory and infectious diseases. The company's mission is to save 100,000 lives and $1.5B in healthcare costs. Utilizing breath-based diagnostics through the development and application of Breath Biopsy®, Owlstone Medical provides high value Breath Biopsy® products and services to pharmaceutical and academic clients including Cleveland Clinic, AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GSK, where the company supports their biomarker discovery or disease research projects.